MAPT and Alzheimer disease: Tau aggregation inhibitors, such as LMTX (leuco-methylthioninium bis(hydromethanesulfonate)), have shown promise by disrupting tau fibril formation, with Phase III trial data suggesting clinical benefits for patients not on concomitant AD medications [29,30].